[1] Robert C., A decade of immune-checkpoint inhibitors in cancer therapy, Nat. Commun., Vol. 11, (2020) , pp. 1–3. https://doi.org/10.1038/s41467-020-17670-y.
[2] Apte R.N., Krelin Y., Song X., Dotan S., Recih E., Elkabets M., Carmi Y., Dvorkin T., White R.M., Gayvoronsky L., Segal S., Voronov E., Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions, Eur. J. Cancer., Vol. 42, (2006) , pp. 751–759. https://doi.org/10.1016/j.ejca.2006.01.010.
[3] Kaplanov I., Carmi Y., Kornetsky R., Shemesh A., Shurin G. V., Shurin M.R., Dinarello C.A., Voronov E., Apte R.N., Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti–PD-1 for tumor abrogation, Proc. Natl. Acad. Sci. U. S. A., Vol. 116, (2019) , pp. 1361–1369. https://doi.org/10.1073/pnas.1812266115.
[4] Aggen D.H., Ager C.R., Obradovic A.Z., Chowdhury N., Ghasemzadeh A., Mao W., Chaimowitz M.G., Lopez-Bujanda Z.A., Spina C.S., Hawley J.E., Dallos M.C., Zhang C., Wang V., Li H., Guo X. V., Drake C.G., Blocking IL1 beta promotes tumor regression and remodeling of the myeloid compartment in a renal cell carcinoma model: multidimensional analyses, Clin. Cancer Res., Vol. 27, (2021) , pp. 608–621. https://doi.org/10.1158/1078-0432.CCR-20-1610.
[5] Z.R. Yurkovetsky, J. M. Kirkwood H.D.E. et al., Multiplex analysis of serum cytokines in melanoma patients treated with interferon-α2b, Clin. Cancer Res., Vol. 13, (2007) , pp. 2422–2428.
[6] Singh S., Singh A.P., Sharma B., Owen L.B., Singh R.K., CXCL8 and its cognate receptors in melanoma progression and metastasis, Future Oncol., Vol. 6, (2010) , pp. 111. https://doi.org/10.2217/FON.09.128.
[7] Jiang H., Gebhardt C., Umansky L., Beckhove P., Schulze T.J., Utikal J., Umansky V., Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients, Int. J. Cancer., Vol. 136, (2015) , pp. 2352–2360. https://doi.org/10.1002/ijc.29297.
[8] Waldner M.J., Foersch S., Neurath M.F., Interleukin-6 - A key regulator of colorectal cancer development, Int. J. Biol. Sci., Vol. 8, (2012) , pp. 1248–1253. https://doi.org/10.7150/ijbs.4614.
[9] Nastase A., Pâslaru L., Niculescu A.M., Ionescu M., Dumitraæcu T., Herlea V., Dima S., Gheorghe C., Lazar V., Popescu I., Prognostic and predictive potential molecular biomarkers in colon cancer, Chir., Vol. 108, (2011) , pp. 177–185. https://europepmc.org/article/med/21696062 (accessed October 12, 2021).
[10] Chen Z.Y., He W.Z., Peng L.X., Jia W.H., Guo R.P., Xia L.P., Qian C.N., A prognostic classifier consisting of 17 circulating cytokines is a novel predictor of overall survival for metastatic colorectal cancer patients, Int. J. Cancer., Vol. 136, (2015) , pp. 584–592. https://doi.org/10.1002/ijc.29017.
[11] Kantola T., Klintrup K., Väyrynen J.P., Vornanen J., Bloigu R., Karhu T., Herzig K.H., Näpänkangas J., Mäkelä J., Karttunen T.J., Tuomisto A., Mäkinen M.J., Stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma, Br. J. Cancer., Vol. 107, (2012) , pp. 1729–1736. https://doi.org/10.1038/bjc.2012.456.
[12] Ueda T., Shimada E., Urakawa T., Serum levels of cytokines in patients with colorectal cancer: Possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis, J. Gastroenterol., Vol. 29, (1994) , pp. 423–429. https://doi.org/10.1007/BF02361238.
[13] Voronov E., Apte R.N., IL-1 in Colon Inflammation, Colon Carcinogenesis and Invasiveness of Colon Cancer, Cancer Microenviron., Vol. 8, (2015) , pp. 187–200. https://doi.org/10.1007/s12307-015-0177-7.
[14] Konturek S.J., Starzynska T., Konturek P.C., Karczewska E., Marlicz K., Lawniczak M., Jaroszewicz-Heigelman H., Bielanski W., Hartwich A., Ziemniak A., Hahn E.G., Helicobacter pylori and CagA status, serum gastrin, interleukin-8 and gastric acid secretion in gastric cancer, Scand. J. Gastroenterol., Vol. 37, (2002) , pp. 891–898. https://doi.org/10.1080/003655202760230838.
[15] Wong H.L., Rabkin C.S., Shu X.O., Pfeiffer R.M., Cai Q., Ji B.T., Yang G., Li H.L., Rothman N., Gao Y.T., Zheng W., Chow W.H., Systemic cytokine levels and subsequent risk of gastric cancer in Chinese Women, Cancer Sci., Vol. 102, (2011) , pp. 1911–1915. https://doi.org/10.1111/j.1349-7006.2011.02033.x.
[16] M. Epplein, Y.-B. Xiang Q.C. et al., Circulating cytokines and gastric cancer risk, Cancer Causes Control., Vol. 24, (2013) , pp. 2245–2250.
[17] K. Kashima and D.Y.G., Relation between cytokines and Helicobacter pylori in gastric cancer, Helicobacter., Vol. 6, (2001) , pp. 116–124.
[18] Tannahill G.M., Curtis A.M., Adamik J., Palsson-Mcdermott E.M., McGettrick A.F., Goel G., Frezza C., Bernard N.J., Kelly B., Foley N.H., Zheng L., Gardet A., Tong Z., Jany S.S., Corr S.C., Haneklaus M., Caffrey B.E., Pierce K., Walmsley S., Beasley F.C., Cummins E., Nizet V., Whyte M., Taylor C.T., Lin H., Masters S.L., Gottlieb E., Kelly V.P., Clish C., Auron P.E., Xavier R.J., O’Neill L.A.J., Succinate is an inflammatory signal that induces IL-1β through HIF-1α, Nature., (2013). https://doi.org/10.1038/nature11986.
[19] Jagielska J., Kapopara P.R., Salguero G., Scherr M., Schütt H., Grote K., Schieffer B., Bavendiek U., Interleukin-1β assembles a proangiogenic signaling module consisting of caveolin-1, Tumor necrosis factor receptor-associated factor 6, p38-mitogen-activated protein kinase (MAPK), and mapk-activated protein kinase 2 in endothelial cells, Arterioscler. Thromb. Vasc. Biol., Vol. 32, (2012) , pp. 1280–1288. https://doi.org/10.1161/ATVBAHA.111.243477.
[20] Tannahill G.M., Curtis A.M., Adamik J., Palsson-Mcdermott E.M., McGettrick A.F., Goel G., Frezza C., Bernard N.J., Kelly B., Foley N.H., Zheng L., Gardet A., Tong Z., Jany S.S., Corr S.C., Haneklaus M., Caffrey B.E., Pierce K., Walmsley S., Beasley F.C., Cummins E., Nizet V., Whyte M., Taylor C.T., Lin H., Masters S.L., Gottlieb E., Kelly V.P., Clish C., Auron P.E., Xavier R.J., O’Neill L.A.J., Succinate is an inflammatory signal that induces IL-1β through HIF-1α, Nature., Vol. 496, (2013) , pp. 238–242. https://doi.org/10.1038/nature11986.
[21] Dirkx A.E.M., oude Egbrink M.G.A., Wagstaff J., Griffioen A.W., Monocyte/macrophage infiltration in tumors: modulators of angiogenesis, J. Leukoc. Biol., Vol. 80, (2006) , pp. 1183–1196. https://doi.org/10.1189/jlb.0905495.
[22] Jung Y.D., Fan F., McConkey D.J., Jean M.E., Liu W., Reinmuth N., Stoeltzing O., Ahmad S.A., Parikh A.A., Mukaida N., Ellis L.M., Role of P38 MAPK, AP-1, and NF-κb in interleukin-1β-induced IL-8 expression in human vascular smooth muscle cells, Cytokine., Vol. 18, (2002) , pp. 206–213. https://doi.org/10.1006/cyto.2002.1034.
[23] Hwang Y.S., Jeong M., Park J.S., Kim M.H., Lee D.B., Shin B.A., Mukaida N., Ellis L.M., Kim H.R., Ahn B.W., Jung Y.D., Interleukin-1b stimulates IL-8 expression through MAP kinase and ROS signaling in human gastric carcinoma cells, Oncogene., Vol. 23, (2004) , pp. 6603–6611. https://doi.org/10.1038/sj.onc.1207867.
[24] Xia W., Chen W., Zhang Z., Wu D., Wu P., Chen Z., Li C., Huang J., Prognostic value, clinicopathologic features and diagnostic accuracy of interleukin-8 in colorectal cancer: A meta-analysis, PLoS One., (2015). https://doi.org/10.1371/journal.pone.0123484.
[25] Schalper K.A., Carleton M., Zhou M., Chen T., Feng Y., Huang S.P., Walsh A.M., Baxi V., Pandya D., Baradet T., Locke D., Wu Q., Reilly T.P., Phillips P., Nagineni V., Gianino N., Gu J., Zhao H., Perez-Gracia J.L., Sanmamed M.F., Melero I., Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors, Nat. Med., Vol. 26, (2020) , pp. 688–692. https://doi.org/10.1038/s41591-020-0856-x.
[26] Kudo S., Mizuno K., Hirai Y., Shimizu T., Clearance and tissue distribution of recombinant human interleukin 1 beta in rats., Cancer Res., Vol. 50, (1990) , pp. 5751–5755.
[27] Castell J. V, Geiger T., Gross V., Andus T., Walter E., Hirano T., Kishimoto T., Heinrich P.C., Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat., Eur. J. Biochem., Vol. 177, (1988) , pp. 357–361. https://doi.org/10.1111/j.1432-1033.1988.tb14384.x.
[28] Redl H., Schlag G., Bahrami S., Schade U., Ceska M., Stütz P., Plasma neutrophil-activating peptide-1/interleukin-8 and neutrophil elastase in a primate bacteremia model., J. Infect. Dis., Vol. 164, (1991) , pp. 383–388. https://doi.org/10.1093/infdis/164.2.383.